NCT05343455 - A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2) | Biotech Hunter

Enrollment

330

Participants

Timeline

Start Date

March 29, 2022

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions

Papulopustular Rosacea

Interventions

DRUG

DFD-29

DFD-29 (40 mg) extended release capsules

DRUG

Doxycycline

Doxycycline 40 mg capsules

DRUG

Placebo

Placebo capsules

Trial Locations (24)

10247

Clinical Trial Site 24, Berlin

22391

Clinical Trial Site 19, Hamburg

29621

Clinical Trial Site 06, Anderson

33027

Clinical Trial Site 05, Miramar

33173

Clinical Trial Site 02, Miami

33175

Clinical Trial Site 14, Miami

33178

Clinical Trial Site 01, Doral

40241

Clinical Trial Site 10, Louisville

42287

Clinical Trial Site 18, Wuppertal

43016

Clinical Trial Site 04, Dublin

44793

Clinical Trial Site 22, Bochum

45246

Clinical Trial Site 09, Cincinnati

46168

Clinical Trial Site 16, Plainfield

47129

Clinical Trial Site 08, Clarksville

48249

Clinical Trial Site 25, Dülmen

48455

Clinical Trial Site 17, Bad Bentheim

64283

Clinical Trial Site 20, Darmstadt

64506

Clinical Trial Site 11, Saint Joseph

66663

Clinical Trial Site 23, Merzig

77056

Clinical Trial Site 03, Houston

78660

Clinical Trial Site 07, Pflugerville

78759

Clinical Trial Site 12, Austin

89129

Clinical Trial Site 21, Langenau

90404

Clinical Trial Site 15, Santa Monica